Tascenso Care Icon

Support

We know that life-changing treatments need a support system which is tailored to the unique challenges your patients face. That’s why we created Cycle Vita, our dedicated patient support program, which delivers individualized product support* at every step. Including:

  • TASCENSO Time Program (baseline assessments and first dose observation)
  • Financial Assistance (including co-pay)
  • Bridge Program
  • Medication Adherence Support
Find out more
Tascenso Dissolve Icon

Product

TASCENSO ODT is the same proven fingolimod you are familiar with, but it comes in a unique orally disintegrating tablet formulation.1

  • Unique orally disintegrating tablet for MS treatment
  • Same proven fingolimod
  • Same efficacy & safety as Gilenya® (fingolimod) capsules
  • Not a generic²
  • Not substitutable at the pharmacy level²
  • Dissolves on the tongue in seconds
  • Once daily, with or without food, with or without water
  • Available as 0.25 mg and 0.5 mg orally disintegrating tablets
  • Every batch tested and verified
Find out more

References

1. TASCENSO ODT (fingolimod). Prescribing Information. Cycle Pharmaceuticals Ltd.
2. FDA., 2024. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available at: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm [Accessed: December 3 2024].
3. Okuda DT, et al. 2024. Clinical and radiological implications of subpotent generic fingolimod in multiple sclerosis: a case series. Therapeutic Advances in Neurological Disorders. 2024;17, 17562864241300047. Available at: https://doi/10.1177/17562864241300047 [Accessed: December 3 2024].
4. Patel, MA, et al. 2025, May 28-31. Clinical and Radiological Outcomes of Directed Treatment Transitions from Gilenya® to Generic Fingolimod [Poster]. CMSC Annual Meeting 2025, Phoenix, AZ, United States. Available at: https://cmsc.confex.com/cmsc/2025/meetingapp.cgi/Paper/10222. [Accessed: June 19 2025].

*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at 888-360-8482.

Gilenya® is a registered trademark of Novartis AG.
Viatris™ is a trademark and Mylan® is a registered trademark of Mylan Inc., a Viatris company.